ArticleJournal of medical biochemistry2026
Diagnostic value and risk correlation of serum heart-type fatty acid-binding protein (H-FABP) and osteoprotegerin (OPG) in chronic heart failure.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To analyse the value of H-FABP and OPG in determining the severity of heart function in those suffering from long-term heart failure. Methods: A total of 196 patients with persistent heart failure who were admitted to our hospital between June 2023 and October 2024 were chosen. A comparison of the three groups of chronic heart failure patients' general clinical information and H-FABP and OPG levels was performed. The associations between OPG and H-FABP and various clinical forms of chronic heart failure, heart failure severity, and measurement markers related to echocardiography were examined. To assess the diagnostic utility of NT-proBNP, H-FABP, and OPG detection alone and in combination for HFrEF and HFpEF patients. All patients were monitored for three to six months following their discharge. Results: There was a positive correlation (r=0.61) between H-FABP and the NYHA classification, LA (r=0.46), LV (r=0.51), HS-TnT (r=0.31), NT-proBNP (r=0.58), SUA (r=0.38), etc., and negatively correlated with the LVEF (r=-0.76), NT-proBNP (r=0.49), etc., and negatively correlated with the LVEF (r=-0.60) (P<0.05). Binary logistic regression analysis of NT-proBNP, H-FABP, and OPG levels and endpoint events revealed that NT-proBNP had a high value in predicting endpoint events. The readmission rate and mortality rate of patients with chronic heart failure increased with increasing NT-proBNP concentration. Serum H-FABP and OPG all have high diagnostic value for HFrEF. Compared with the traditional biomarker NT-proBNP, H-FABP had greater sensitivity (94.9%) and specificity (83.1%) in the diagnosis of HFrEF, whereas OPG had greater sensitivity (92.3%) and lower specificity (57.7%). H-FABP and OPG can significantly improve the sensitivity (86.44%) and specificity (89.74%) in the diagnosis of patients with HFrEF. Serum NT-proBNP, H-FABP and OPG all have high diagnostic value for HFpEF. Compared with the traditional biomarker NT-proBNP, H-FABP has greater sensitivity (91.7%) and specificity (82.0%) in the diagnosis of HFpEF, whereas OPG has greater specificity (82.0%) and lower sensitivity (58.3%). Conclusions: The combined detection of H-FABP, OPG, and NT-proBNP can be used as an essential strategy for the early detection of decreased cardiac function in heart failure patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.